192 related articles for article (PubMed ID: 25202818)
1. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease.
Roussel R; Fezeu L; Marre M; Velho G; Fumeron F; Jungers P; Lantieri O; Balkau B; Bouby N; Bankir L; Bichet DG
J Clin Endocrinol Metab; 2014 Dec; 99(12):4656-63. PubMed ID: 25202818
[TBL] [Abstract][Full Text] [Related]
2. Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.
Roussel R; Matallah N; Bouby N; El Boustany R; Potier L; Fumeron F; Mohammedi K; Balkau B; Marre M; Bankir L; Velho G
Am J Nephrol; 2015; 42(2):107-14. PubMed ID: 26346607
[TBL] [Abstract][Full Text] [Related]
3. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
[TBL] [Abstract][Full Text] [Related]
4. Modifiable factors associated with copeptin concentration: a general population cohort.
van Gastel MD; Meijer E; Scheven LE; Struck J; Bakker SJ; Gansevoort RT
Am J Kidney Dis; 2015 May; 65(5):719-27. PubMed ID: 25500109
[TBL] [Abstract][Full Text] [Related]
5. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients.
Meijer E; Bakker SJ; de Jong PE; Homan van der Heide JJ; van Son WJ; Struck J; Lems SP; Gansevoort RT
Transplantation; 2009 Aug; 88(4):561-7. PubMed ID: 19696640
[TBL] [Abstract][Full Text] [Related]
6. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
[TBL] [Abstract][Full Text] [Related]
7. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Nakajima A; Lu Y; Kawano H; Horie S; Muto S
Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
[TBL] [Abstract][Full Text] [Related]
8. Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.
El Boustany R; Tasevska I; Meijer E; Kieneker LM; Enhörning S; Lefèvre G; Mohammedi K; Marre M; Fumeron F; Balkau B; Bouby N; Bankir L; Bakker SJ; Roussel R; Melander O; Gansevoort RT; Velho G
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997293
[TBL] [Abstract][Full Text] [Related]
9. Gender and renal function influence plasma levels of copeptin in healthy individuals.
Bhandari SS; Loke I; Davies JE; Squire IB; Struck J; Ng LL
Clin Sci (Lond); 2009 Feb; 116(3):257-63. PubMed ID: 18647134
[TBL] [Abstract][Full Text] [Related]
10. Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population.
Tasevska I; Enhörning S; Christensson A; Persson M; Nilsson PM; Melander O
Am J Nephrol; 2016; 44(1):22-8. PubMed ID: 27347674
[TBL] [Abstract][Full Text] [Related]
11. The Vasopressin System in the Risk of Diabetes and Cardiorenal Disease, and Hydration as a Potential Lifestyle Intervention.
Enhörning S; Melander O
Ann Nutr Metab; 2018; 72 Suppl 2():21-27. PubMed ID: 29925066
[TBL] [Abstract][Full Text] [Related]
12. Copeptin Associates with Cause-Specific Mortality in Patients with Impaired Renal Function: Results from the LURIC and the 4D Study.
Krane V; Genser B; Kleber ME; Drechsler C; März W; Delgado G; Allolio B; Wanner C; Fenske W;
Clin Chem; 2017 May; 63(5):997-1007. PubMed ID: 28280053
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
14. Copeptin Plasma Levels are Associated with Decline of Renal Function in Patients with Type 2 Diabetes Mellitus.
Villela-Torres ML; Higareda-Mendoza AE; Gómez-García A; Alvarez-Paredes AR; García-López E; Stenvikel P; Gu HF; Rashid-Qureshi A; Lindholm B; Alvarez-Aguilar C
Arch Med Res; 2018 Jan; 49(1):36-43. PubMed ID: 29665969
[TBL] [Abstract][Full Text] [Related]
15. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.
Blanchard A; Steichen O; De Mota N; Curis E; Gauci C; Frank M; Wuerzner G; Kamenicky P; Passeron A; Azizi M; Llorens-Cortes C
J Clin Endocrinol Metab; 2013 May; 98(5):2084-9. PubMed ID: 23515451
[TBL] [Abstract][Full Text] [Related]
16. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States.
Balanescu S; Kopp P; Gaskill MB; Morgenthaler NG; Schindler C; Rutishauser J
J Clin Endocrinol Metab; 2011 Apr; 96(4):1046-52. PubMed ID: 21289257
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease.
Golembiewska E; Machowska A; Stenvinkel P; Lindholm B
Curr Protein Pept Sci; 2017; 18(12):1232-1243. PubMed ID: 28714397
[TBL] [Abstract][Full Text] [Related]
18. Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.
Sontrop JM; Huang SH; Garg AX; Moist L; House AA; Gallo K; Clark WF
BMJ Open; 2015 Nov; 5(11):e008634. PubMed ID: 26603245
[TBL] [Abstract][Full Text] [Related]
19. Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Jun; 42(5):1808-11. PubMed ID: 20620528
[TBL] [Abstract][Full Text] [Related]
20. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
